Devonian Health Group Inc. (CVE:GSD – Get Free Report) was up 4.2% during trading on Thursday . The company traded as high as C$0.25 and last traded at C$0.25. Approximately 44,980 shares were traded during trading, an increase of 124% from the average daily volume of 20,061 shares. The stock had previously closed at C$0.24.
Devonian Health Group Trading Up 4.2 %
The business’s 50-day moving average price is C$0.20 and its 200 day moving average price is C$0.18. The company has a debt-to-equity ratio of 16.36, a current ratio of 1.07 and a quick ratio of 7.82. The firm has a market capitalization of C$37.06 million, a price-to-earnings ratio of -12.50 and a beta of 1.28.
About Devonian Health Group
Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics.
Further Reading
- Five stocks we like better than Devonian Health Group
- Why is the Ex-Dividend Date Significant to Investors?
- Everything About Amazon Stock Signals a Buy—Time to Load Up?
- What Are Some of the Best Large-Cap Stocks to Buy?
- 5 Reasons Five Below’s Stock Price Is Heading Higher This Year
- 3 Tickers Leading a Meme Stock Revival
- Broadcom: Why the Chip Stock Remains a Top Long-Term AI Play
Receive News & Ratings for Devonian Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Devonian Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
